Video

Dr Jeanne Tie on How ctDNA Helps Guide Decisions in Cancer Care

Circulating tumor DNA (ctDNA) can now allow clinicians to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy, said Jeanne Tie, MBChB, FRACP, MD, medical oncologist and associate professor at the Walter+Eliza Hall Institute of Medical Research.

Circulating tumor DNA (ctDNA) can now allow clinicians to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy, said Jeanne Tie, MBChB, FRACP, MD, medical oncologist and associate professor at the Walter+Eliza Hall Institute of Medical Research.

Transcript

For patients who are in early stages of cancer, how can tests that analyze circulating tumor DNA help guide decisions in a way that wasn't possible before?

So, what a ctDNA can offer now is that it can detect microscopic disease after surgery and determine or identify those at a very high risk of recurrence and those at low risk of recurrence. That would guide clinicians as to who would need to be offered adjuvant chemotherapy or intensified chemotherapy, compared to those with low-risk disease who they can de-escalate or even avoid chemotherapy and its associated side effects.

Related Videos
Jawad Haider Butt, MD, PhD
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Andrew Kuykendall, MD, Moffitt Cancer Center
Anna Mueller, MD, Mount Sinai
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo